Mifepristone and misoprostol (combination pack)
Brand names: Mifegyne + Topogyne, MTPak
This is a combination pack pairing the antiprogestogen mifepristone with the prostaglandin analogue misoprostol, used sequentially for medical termination of pregnancy and management of miscarriage.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Mifepristone blocks progesterone receptors, sensitising the myometrium and softening the cervix, after which misoprostol stimulates uterine contractions and cervical ripening to complete expulsion.
Prescribing in practice
- Mifepristone is taken first and misoprostol after an interval; warn that significant bleeding and cramping are expected and that the woman must have access to urgent care for haemorrhage or signs of incomplete or continuing pregnancy.
- It should be used within an appropriate provider framework with confirmation of gestation and exclusion of contraindications such as suspected ectopic pregnancy, an in-situ intrauterine device, chronic adrenal failure or severe uncontrolled asthma.
- If the pregnancy continues after exposure there is a recognised risk of fetal harm, so treatment failure must be actively followed up.
Monitoring
Confirm successful completion clinically or with follow-up testing, and assess bleeding, pain and any signs of infection or retained products.
Counselling the patient
- Take the mifepristone first, then the misoprostol after the interval your clinician specifies.
- Heavy bleeding and cramping are expected; seek urgent help for very heavy bleeding, fever, severe pain or feeling faint.
- Attend any follow-up to confirm the process is complete, and start contraception when advised.
Evidence & guidelines
Sequential mifepristone followed by misoprostol is the regimen recommended by NICE and the RCOG for medical termination and miscarriage management.
Reference: RCOG / NICE NG140; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- IMPROVE VTE Risk Score for Medical Patients · VTE Risk
- EpiScore for Epistaxis Severity · Epistaxis
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Padua Prediction Score for VTE Risk in Medical Inpatients · Venous Thromboembolism
- Pack Years Calculator for Smoking History · Oncology Risk
- Spinal Anaesthesia Hypotension Management · AAGBI; ASA
- Pre-Eclampsia / Eclampsia in ED · NICE NG133; RCOG Green-top 10A
- Suspected Ectopic Pregnancy · NICE NG126; RCOG Green-top 21
- Polycystic Ovary Syndrome (PCOS) · International PCOS Guideline 2023; NICE CKS
- Pre-eclampsia Management · NICE NG133 2019
- Ectopic Pregnancy · NICE CG154 / RCOG GTG 21